Emma Meadows
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Genetics top 5%
- Genetic Associations and Epidemiology
Papers in
-
- COVID-19 Clinical Research Studies 8
- Infection Control in Healthcare 1
- Genetics 6
- Genetic Associations and Epidemiology 6
Emma Meadows
15 papers receiving 2.6k citations
Emma Meadows's Hit Papers
Peers
Comparison fields: 5 of 98
- Infectious Diseases 1.8k
- Genetics 514
- Applied Microbiology and Biotechnology 35
- Internal Medicine 28
- Immunology 129
Countries citing papers authored by Emma Meadows
This map shows the geographic impact of Emma Meadows's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Meadows with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Meadows more than expected).
Fields of papers citing papers by Emma Meadows
This network shows the impact of papers produced by Emma Meadows. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Meadows. The network helps show where Emma Meadows may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 4 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 5 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 6 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 7 | 2021 | 213 | |
| 8 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 9 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 10 | 2023 | 60 | |
| 11 | 2022 | 33 | |
| 12 | 2024 | 8 | |
| 13 | 2020 | 7 | |
| 14 | 2022 | 2 | |
| 15 | 2020 | 1 | |
| 16 | 2021 | 0 |
About Emma Meadows
Emma Meadows is a scholar working on Infectious Diseases, Genetics, Obstetrics and Gynecology, Oncology and Anesthesiology and Pain Medicine, having authored 16 papers that have together received 2.7k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (8 papers), Genetic Associations and Epidemiology (6 papers), COVID-19 and healthcare impacts (2 papers), COVID-19 Impact on Reproduction (2 papers), Infection Control and Ventilation (1 paper), Pregnancy and preeclampsia studies (1 paper), Anesthesia and Sedative Agents (1 paper) and Infection Control in Healthcare (1 paper). The work is most often cited by research in Infectious Diseases (1.8k citations), Genetics (514 citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (28 citations) and Immunology (129 citations). Emma Meadows has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Their work appears in journals such as The Lancet, Nature, European Journal of Obstetrics & Gynecology and Reproductive Biology, International Journal of Obstetric Anesthesia and Human Genetics and Genomics Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.